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Abstract
Background: Differentiation-inducing factor-1 (DIF-1) is a putative morphogen that induces cell differentiation in
Dictyostelium discoideum. DIF-1 inhibits proliferation of various mammalian tumor cells by suppressing the
canonical Wnt/b-catenin signaling pathway. To assess the potential of a novel cancer chemotherapy based on the
pharmacological effect of DIF-1, we investigated whether DIF-1 exhibits anti-angiogenic effects in vitro and in vivo.
Results: DIF-1 not only inhibited the proliferation of human umbilical vein endothelial cells (HUVECs) by restricting
cell cycle in the G0/G1 phase and degrading cyclin D1, but also inhibited the ability of HUVECs to form capillaries
and migrate. Moreover, DIF-1 suppressed VEGF- and cancer cell-induced neovascularization in Matrigel plugs
injected subcutaneously to murine flank. Subsequently, we attempted to identify the mechanism behind the anti-
angiogenic effects of DIF-1. We showed that DIF-1 strongly decreased vascular endothelial growth factor receptor-2
(VEGFR-2) expression in HUVECs by inhibiting the promoter activity of human VEGFR-2 gene, though it was not
caused by inhibition of the Wnt/b-catenin signaling pathway.
Conclusion: These results suggested that DIF-1 inhibits angiogenesis both in vitro and in vivo, and reduction of
VEGFR-2 expression is involved in the mechanism. A novel anti-cancer drug that inhibits neovascularization and
tumor growth may be developed by successful elucidation of the target molecules for DIF-1 in the future.
Background
Angiogenesis is a multi-step process essential for tumor
growth and metastasis, which involves endothelial cell
proliferation, migration and capillary formation [1-4].
Among many soluble and matrix-derived angiogenic
growth factors and regulators of angiogenesis involved
in neovascularization, vascular endothelial growth factor
(VEGF) plays a crucial role in the proliferation, migra-
tion and survival of vascular endothelial cells [2,5-7].
The VEGF family consists of six members, VEGF-A,
VEGF-B, VEGF-C, VEGF-D, VEGF-E and the placenta
growth factor (PLGF) [4,7,8]. Among them, VEGF-A is
known as the most important factor for many
angiogenic processes. VEGF-A binds to two tyrosine
kinase receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/
Flk-1) [2,8-11]. Signaling through VEGFR-1 is related to
embryonic angiogenesis and acts as a regulator of
VEGFR-2 [7,8,12,13]. Althought h ea f f i n i t yo fV E G F R - 2
for VEGF is lower than that of VEGFR-1, VEGFR-2 is
more potent than VEGFR-1 in stimulating endothelial
cell proliferation and migration [11,14]. VEGFR-2
expression is almost restricted to vascular endothelial
cells and it has been reported that VEGFR-2 expression
was markedly up-regulated during chronic inflamma-
tion, wound repair and tumor growth [5,15,16].
Differentiation-inducing factors (DIFs) were identified
in Dictyostelium discoideum as morphogens required for
stalk cell differentiation [17]. In the DIF family, DIF-1
(1-(3, 5-dichloro-2, 6-dihydroxy-4-methoxyphenyl)-1-
hexanone) was the first to be identified. The actions of
* Correspondence: yanaga@clipharm.med.kyushu-u.ac.jp
1Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu
University, Fukuoka 812-8582, Japan
Full list of author information is available at the end of the article
Yoshihara et al. Molecular Cancer 2010, 9:245
http://www.molecular-cancer.com/content/9/1/245
© 2010 Yoshihara et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.DIFs are not limited to Dictyostelium and they strongly
inhibit the proliferation of human cells [18,19]. Pre-
viously, we reported that DIFs inhibited the Wnt/b-cate-
nin signaling pathway via glycogen synthase kinase-3b
(GSK-3b) activation, leading to cell cycle arrest at G0/G1
phase through suppression of cyclin D1 expression in
various human tumor cells [20-23]. It is well known
that the Wnt/b-catenin signaling pathway plays a num-
ber of key roles in embryonic development and mainte-
nance of homeostasis in matured tissues. And also, this
signaling pathway has been reported to play important
roles in the proliferation and migration of endothelial
cells, resulting in the promotion of angiogenesis [24-28].
In this study, we investigated the effect of DIF-1 on
angiogenesis in in vitro and in vivo systems. We
revealed that DIF-1 decreased the expression of VEGFR-
2 in protein and mRNA levels via the suppression of the
promoter activity by a Wnt/b-catenin signaling path-
way-independent mechanism. Our results suggest that
the suppression of VEGFR-2 expression could be one
mechanism of the inhibition of angiogenesis induced by
DIF-1 and that DIF-1 suppressed not only the Wnt/b-
catenin signaling pathway but also neovascularization.
Results
DIF-1 inhibited HUVEC proliferation
DIF-1 exhibits powerful anti-proliferative effects in var-
ious mammalian cells [18-23] and we previously
reported that DIF-3 induced cell cycle arrest by redu-
cing cyclin D1 in HUVECs [20]. In this present study,
we first examined whether DIF-1 also inhibited HUVEC
proliferation. As shown in Figure 1A, DIF-1 strongly
inhibited HUVEC proliferation in a dose-dependent
manner. This anti-proliferative effect was unlikely to be
caused by cytotoxicity, because the number of dead cells
indicated by the trypan blue exclusion test was not
increased by treatment with DIF-1 (data not shown).
We next examined the effects of DIF-1 on cell cycle dis-
tribution using flow cytometry. As shown in Figure 1B,
the cell population in the G0/G1 phase significantly
increased and the population in S and G2/M phases
decreased, indicating that DIF-1 induced G0/G1 arrest in
HUVECs. These results were consistent with that pub-
lished in our previous reports [19-21].
DIF-1 induced proteolysis of cyclin D1 in HUVECs
We previously reported that DIF-1 had strong effects on
cyclin D1 protein level [21,22]. Therefore, we examined
the effects of DIF-1 on cyclin D1 protein quantity using
HUVECs. DIF-1 rapidly reduced the protein level of cyclin
D1 in time- and dose-dependent manners (Figure 2A and
2B, respectively). Next, we examined the effects of protea-
some inhibitor MG132, since cyclin D1 has been reported
to be degraded by ubiquitin-dependent proteolysis.
MG132 significantly attenuated the effects of DIF-1, indi-
cating that DIF-1 induced proteolysis of cyclin D1 in
HUVECs (Figure 2C).
DIF-1 inhibited angiogenesis in vitro
To evaluate the effects of DIF-1 on angiogenesis in vitro,
we performed tube formation assay. HUVECs formed
blood vessel-like structure (tubes) on Matrigel-coated
wells following incubation for 8 h. However, DIF-1-trea-
ted HUVECs almost failed to form vessel-like structures
and the number of areas surrounded by tubes was sig-
nificantly smaller than that in control cells (Figure 3A).
Subsequently, the effects of DIF-1 on HUVECs migra-
tion were evaluated using a Boyden Chamber. Although
the cells migrated into the lower chamber even in the
a b s e n c eo fV E G F ,t h en u m b e ro fm i g r a t i n gc e l l s
increased by about 30% when VEGF was added to the
lower chamber. Therefore, VEGF was added to the
lower chamber when the effect of DIF-1 was investi-
gated. Although VEGF in the lower chamber induced
cell migration after incubation for 10 h, DIF-1 signifi-
cantly reduced the number of migrated cells (Figure 3B).
These results clearly indicated that DIF-1 inhibited
angiogenesis in vitro.
DIF-1 inhibited angiogenesis in vivo
We examined the effects of DIF-1 on angiogenesis
in vivo by Matrigel plug assay. VEGF containing-Matri-
gel was prepared with or without DIF-1 (30 μM) and
injected into the flanks of mice. As shown in Figure 4,
blood vessels indicated by the expression of PECAM-1/
CD31, an endothelial cell-specific antigen, were strongly
induced into the injected Matrigel plugs. On the other
hand, the level of PECAM-1/CD31 expression was sig-
nificantly lower in DIF-1-containing Matrigel plugs than
in the control plugs, indicating the presence of fewer
blood vessels.
Subsequently, we examined the effects of DIF-1 on
tumor-induced angiogenesis using HeLa cells. Two
weeks after injection, Matirgel/HeLa cell mixture formed
tumor mass and blood vessels were grown into the
mass. Immunohistochemical analysis of PECAM-1/
CD31 in tumor masses clearly showed that the content
of blood vessels was much less in DIF-1-containing
masses (Figure 5A-I). This finding was also confirmed
by Western blot analysis. As shown in Figure 5J, the
level of PECAM-1/CD31 expression was significantly
lower in DIF-1-containing masses than in the control
masses. These results indicated that DIF-1 inhibited
blood vessel growth induced by VEGF and tumor cells.
DIF-1 decreased VEGFR-1 and VEGFR-2 protein expression
It is well known that VEGF-A, a major regulator for
angiogenesis, binds to VEGFR-1 (Flt-1) and VEGFR-2
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Page 2 of 15(KDR/Flk-1) to transduce its signal. To clarify the
mechanism by which DIF-1 suppresses angiogenesis,
first we examined the effects of DIF-1 on VEGFR-1 and
VEGFR-2 expression in HUVECs by Western blot ana-
lysis. As shown in Figure 6A, although DIF-1 signifi-
cantly reduced the expression of both receptors in
HUVECs, the effect was much stronger in VEGFR-2
than VEGFR-1.
VEGF increases VEGFR-2 phosphorylation on Tyr
1175
for activation [29-31]. Although DIF-1 decreased the
phosphorylation level of Tyr
1175 on VEGFR-2 in a time-
dependent manner, it was parallel with the time course
of the VEGFR-2 protein amount, indicating that DIF-1
had no significant effects on the level of VEGFR-2 phos-
phorylation (Figure 6B).
DIF-1 reduced VEGFR-2 protein synthesis
To clarify the mechanism of DIF-1-induced VEGFR-2
protein suppression, we first examined the effects of
DIF-1 on VEGFR-2 degradation using protein synthesis
inhibitor cycloheximide. As shown in Figure 7A, DIF-1
did not accelerate reduction in VEGFR-2 protein quan-
tity, indicating that DIF-1 had no significant effects on
VEGFR-2 proteolysis.
Next, we investigated VEGFR-2 protein synthesis.
HUVECs were pretreated with cycloheximide for 3 h
and then the medium was changed to fresh growth
medium to wash out cycloheximide. As shown in Figure
7B, after VEGFR-2 protein disappeared following cyclo-
heximide treatment, it was rapidly restored and reached
a plateau after 1 h incubation. However, restoration of
VEGFR-2 protein was significantly delayed by DIF-1
treatment.
DIF-1 suppressed VEGFR-2 mRNA level and VEGFR-2
promoter activity
Subsequently, we examined the effect of DIF-1 on the
mRNA expression of VEGFR-2 in HUVECs by real-time
PCR analysis and found that DIF-1 significantly sup-
pressed VEGFR-2 mRNA level (Figure 8A). We further
examined the effects of DIF-1 on human VEGFR-2 gene
promoter activity using a luciferase reporter plasmid.
Since the efficiency of DNA transfection in HUVECs
was low (10% to 20%), we also employed BAECs in
which transfection efficiency was much higher (60% to
70%) [32]. As shown in Figure 8B and 8C, luciferase
reporter activity driven by the 5’-flanking region of
h u m a nV E G F R - 2g e n ei nH U V E C s( B )o rB A E C s( C )
was increased as incubation proceeded. However, the
promoter activity was not significantly increased in DIF-
1-treated HUVECs and BAECs. Therefore DIF-1
appeared to suppress VEGFR-2 protein and mRNA
expressions by inhibiting the promoter activity in
HUVECs.
Figure 1 DIF-1 inhibited HUVECs proliferation. (A) Cell proliferation assay. HUVECs seeded on a 24-well plate (1.0×10
4 cells/well) were
incubated with various amount of DIF-1. Cells were harvested by trypsin/EDTA treatment at the times indicated and enumerated. Values are
mean ± SE of three independent experiments and statistically analyzed using a one-way ANOVA with Bonferroni post-hoc test. The asterisk
indicates *P < 0.05 and **P < 0.01 versus control. (B) Flow cytometry. HUVECs were incubated with DIF-1 (30 μM) for 24 h and then harvested
by the trypsin/EDTA treatment. Cells were stained with propidium iodide (PI) and fluorescence of nuclei was measured. The percentages of cell
number in the cell cycle phases are also shown. The results are means ± SE of three independent experiments. The asterisk indicates *P < 0.01
and **P < 0.001 versus control.
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As previously reported, DIF-1 suppressed the Wnt/b-
catenin signaling pathway by activating GSK-3b in
tumor cells. Moreover, the Wnt/b-catenin signaling
pathway has been shown to play an important role in
promoting angiogenesis. Therefore, we examined the
involvement of the Wnt/b-catenin signaling pathway in
DIF-1-induced VEGFR-2 suppression. As shown in Fig-
ure 9A, DIF-1 significantly inhibited TOPflash (TCF
reporter plasmid) activity, whereas it did not affect FOP-
flash (negative control) activity. Furthermore, as shown
in Figure 9B, DIF-1 reduced the phosphorylation level of
Ser
9 on GSK-3b, indicating that DIF-1 certainly
inhibited the Wnt/b-catenin signaling pathway by acti-
vating GSK-3b in HUVECs.
Although VEGF is one of the target genes of the Wnt/
b-catenin signaling pathway [33,34], it has not been elu-
cidated whether VEGFR-2 gene also belongs to the tar-
get genes of this signaling pathway. Therefore, the
effects of Wnt3a as an activator of the Wnt/b-catenin
signaling pathway on VEGFR-2 protein expression were
examined. Although the amount of VEGFR-2 protein
was increased after a 24 h-incubation period, treatment
with Wnt3a suppressed VEGFR-2 protein increase
(Figure 10A). This observation was confirmed by the
luciferase reporter assay using the 5’-flanking region of
Figure 2 The effect of DIF-1 on cyclin D1 protein amount. (A) Time-course. HUVECs were incubated with or without DIF-1 (30 μM) for the
periods indicated. Samples were subjected to Western blot analysis using the anti-cyclin D1 antibody. The membrane was re-probed with the
anti-GAPDH antibody. The levels of protein bands were quantified and shown as percentages of the control level at time 0. Values are mean ±
SE of three independent experiments. The asterisk indicates *P < 0.01 and **P < 0.001 versus control. (B) Dose dependency. HUVECs were
incubated with or without various amount of DIF-1 for 4 h. Samples were subjected to Western blot analysis using the anti-cyclin D1 antibody.
The membrane was re-probed with the anti-GAPDH antibody. The levels of protein bands were quantified and shown as percentages of the
control level. Values are mean ± SE of three independent experiments. The asterisk indicates *P < 0.001 versus control. (C) Effect of MG132.
HUVECs were pretreated with MG132 (10 μM) for 3 h and incubated with or without DIF-1 (30 μM) for 6 h. Samples were subjected to Western
blot analysis using the anti-cyclin D1 antibody and the membrane was re-probed with the anti-GAPDH antibody. The levels of protein bands are
quantified and shown as percentages of the degraded amounts. Values are mean ± SE of three independent experiments. The asterisk indicates
*P < 0.01 and versus control.
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Page 4 of 15the human VEGFR-2 gene. As shown in Figure 10B,
Wnt3a suppressed VEGFR-2 promoter activity slightly
but significantly in HUVECs, whereas it clearly
increased TOPflash activity. These results indicated that
Wnt3a suppressed VEGFR-2 expression via inhibition of
promoter activity, suggesting that VEGFR-2 gene
expression was suppressed by activating the Wnt/
b-catenin signaling pathway.
Taken together, although DIF-1 suppressed the Wnt/
b-catenin signaling pathway in HUVECs as well as
tumor cells, inhibition of VEGFR-2 promoter activity
induced by DIF-1 was not due to suppression of this
signaling pathway.
Discussion
In this study, we demonstrated that DIF-1 strongly
inhibited angiogenesis in vitro and in vivo.A si ti s
known that VEGF-A signal plays a prominent role in
angiogenesis, we paid special attention to two types of
VEGF receptors, VEGFR-1 and VEGFR-2. Although
DIF-1 decreased the levels of protein expression of both
receptors on HUVECs, the effects were faster and stron-
ger in VEGFR-2 than VEGFR-1. Activation of VEGFR-2
by VEGF-A depends on the phosphorylation status of
several tyrosine residues (such as 951, 1059, 1175, and
1214) in VEGFR-2. Among these tyrosine residues,
Tyr
1175 is the binding site of phospholipase-Cg,am a i n
signal transducer of VEGFR-2 [32-34]. However, as
s h o w ni nF i g u r e6 B ,D I F - 1d i dn o th a v es i g n i f i c a n t
effects on the Tyr
1175 phosphorylation status, suggesting
that DIF-1 did not affect VEGFR-2 activation. Since
VEGFR-2 is a direct signal transducer for pathological
angiogenesis as observed in cancers, the powerful reduc-
tion of VEGFR-2 protein levels may be involved in DIF-
1 induced anti-angiogenic effects.
We also attempted to clarify the mechanism by which
DIF-1 reduced the amount of VEGFR-2 protein. DIF-1
affected the synthesis rather than proteolysis of VEGFR-
2. This was consistent with the result that DIF-1 inhib-
ited the mRNA expression and promoter activity of
VEGFR-2. However, degrees of suppression of the
mRNA expression (29%) and promoter activity (24%)
were relatively small compared to VEGFR-2 protein
quantity suppression (93%) after 24 h-treatment with
DIF-1. The same sort of phenomenon was also observed
by Wnt3a (16% promoter activity suppression vs. 34%
Figure 3 DIF-1 inhibited in vitro angiogenesis. (A) DIF-1 inhibited tube formation of HUVECs. HUVECs were seeded in Matrigel-coated well
with or without DIF-1 30 μM and incubated for 8 h. The tube formation of control HUVECs was normalized as 100%. Each value represents the
mean ± SE of three independent experiments. The asterisk indicates *P < 0.01 versus control. The scale bars indicate 200 μm. (B) DIF-1 inhibited
the migration of HUVECs. HUVECs were seeded into the upper part of Boyden chamber. The lower compartments were filled with 600 μlo f
DMEM supplemented with 0.1% bovine serum albumin and 20 ng/ml (0.52 nM) VEGF. After HUVECs were incubated for 10 h, the migrated cells
on the lower surface of the membrane were quantified by counting the number of cells in ten random fields per membrane and expressed as
cells/fields (mean ± SE). Data are representative of three other experiments. The asterisk indicates *P < 0.01 versus control. The scale bars
indicate 500 μm.
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Page 5 of 15Figure 4 DIF-1 suppressed VEGF-induced angiogenesis in Matrigel plug. VEGF-containing Matrigel was injected subcutaneously into the
flanks of 6-week old C57/BL6 mice. Seven days later, Matrigel plug was extracted and embedded in paraffin. Sections were stained with
hematoxylin-eosin staining (A-D) and immunofluorescence staining using PECAM-1(CD31) (E-H) (Higher magnification of the boxed areas in A, C,
E and G are shown in B, D, F and H, respectively). The scale bars indicate 500 μm. (I) The expression of PECAM-1 (CD31) was analyzed with
fluorescence microscopy and expressed as the strength of fluorescence in Matrigel-plug (mean ± SE) of three independent experiments. The
asterisk indicates *P < 0.05 versus control.
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Page 6 of 15Figure 5 DIF-1 inhibited angiogenesis in xenograft tumor. (A-I) DIF-1 suppressed human cervical carcinoma cell line (HeLa)-induced
angiogenesis. HeLa cells mixed with liquid Matrigel in the presence or absence of 30 μM of DIF-1 were injected subcutaneously into the flanks
of nude mice. The removed tumor sections were stained with hematoxylin-eosin staining (A-D) and immunofluorescence staining using PECAM-
1(CD31) (E-H) (Higher magnification of the boxed areas in A, C, E and G are shown in B, D, F and H, respectively). The scale bars indicate 500
μm. (I) The expression of PECAM-1 (CD31) was analyzed with fluorescence microscopy and expressed as the mean strength of fluorescence in
Matrigel-plug (mean ± SE) of three independent experiments. (J) DIF-1 suppressed PECAM-1 protein expression in the removed tumors. The
samples of the removed tumor were subjected to Western blot analysis using the anti-PECAM-1 (CD31) antibody. The membrane was re-probed
with the anti-GAPDH antibody. The levels of protein bands were quantified and are shown as percentage of the control level. Values are mean ±
SE of three independent experiments. The asterisk indicates *P < 0.05, **P < 0.001 versus control.
Yoshihara et al. Molecular Cancer 2010, 9:245
http://www.molecular-cancer.com/content/9/1/245
Page 7 of 15Figure 6 The effects of DIF-1 on VEGF receptors, VEGFR-1 and VEGFR-2. (A) DIF-1 decreased VEGFR-1 and VEGFR-2 expression in HUVECs.
HUVECs were incubated with or without DIF-1 (30 μM) for the periods indicated and the samples were subjected to Western blot analysis for
VEGFR-1 and VEGFR-2. The levels of protein bands were quantified and are shown as percentage of the control level at time 0. Values are mean
± SE of three independent experiments. The asterisk indicates *P < 0.05 **P < 0.001 versus control. (B) DIF-1 did not affect phosphorylation level
of VEGFR-2. HUVECs were incubated with or without DIF-1 (30 μM) for the periods indicated and the samples were subjected to Western blot
analysis using anti-phospho-VEGFR-2 (Tyr
1175) antibody. The membrane was re-probed with anti-VEGFR-2 antibody. The levels of protein bands
were quantified and are shown as percentage of the control level at time 0. Values are mean ± SE of three independent experiments.
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Page 8 of 15protein quantity suppression). Although we could not
explain this difference at present, the short half-life of
VEGFR-2 protein of about 1 h [35] could be associated
with this phenomenon. In other words, as the proteoly-
sis of VEGFR-2 is quick and rapid synthesis is required
to restore VEGFR-2, even weak inhibition of promoter
activity may significantly affect the quantity of VEGFR-2
protein.
S i n c ew eh a v es h o w nt h a tD I F - 1i n h i b i t st h eW n t / b-
catenin signaling pathway in various cells, the effects of
DIF-1 on the Wnt/b-catenin signaling pathway in
HUVECs were examined. We found that DIF-1 also
inhibited this signaling pathway via GSK-3b activation
in HUVECs. Although the Wnt/b-catenin signaling
pathway has been reported to be important to promote
angiogenesis in vitro [24-28], the role of Wnt/b-catenin
signaling pathway in endothelial cells and angiogenesis
is controversial. Cheng et al.r e p o r t e dt h a tW n t 1
signaling inhibits HUVEC proliferation [36]. On the
other hand, it has been reported that Wnt1 and 3a
mediated induction of VEGFR-2 (Quek-1) expression
during avian somite development [37]. In this study, we
showed that Wnt3a slightly but significantly reduced
promoter activity and VEGFR-2 protein expression.
Therefore, suppression of VEGFR-2 expression induced
by DIF-1 may not be due to suppression of the Wnt/b-
catenin signaling pathway. Our results might suggest
that activation of the Wnt/b-catenin signaling pathway
suppressed the promotion of angiogenesis. However,
Samarzija et al. showed that although Wnt3a stimulated
HUVEC proliferation and migration independent of
VEGFR signaling [38]. Therefore, further studies are
needed to elucidate the relationship between the Wnt/
b-catenin signaling pathway and angiogenesis.
Cyclin D1 plays a key role in the initiation and pro-
gression of the G1 phase [39]. We previously showed
Figure 7 The effects of DIF-1 on the proteolysis and the proteosynthesis of VEGFR-2. (A) DIF-1 did not affect the degradation speed of
VEGFR-2. HUVECs were incubated with or without DIF-1 (30 μM) for the given periods in the presence of cycloheximide (10 μM). Protein
samples were subjected to Western blot analysis for VEGFR-2. The membrane was re-probed with anti-GAPDH antibody. The levels of protein
bands were quantified and are shown as percentage of the control level at time 0. Values are mean ± SE of three independent experiments. (B)
DIF-1 attenuated the protein synthesis of VEGFR-2. After HUVECs were pretreated with cycloheximide (10 μM) for 3 h, the medium was changed
to fresh medium and cells were incubated with or without DIF-1 (30 μM) for the given periods. Protein samples were subjected to Western blot
analysis for VEGFR-2. The membrane was re-probed with anti-GAPDH antibody. The levels of protein bands were quantified and are shown as
percentage of the control cells which were not treated with cycloheximide (lane 1). Values are mean ± SE of three independent experiments.
The asterisk indicates *P < 0.001 versus control.
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induced cell cycle arrest in G0/G1 phase using various
mammalian cells [19,21,22]. In this study, we also
demonstrated that DIF-1 inhibited HUVECs prolifera-
tion and induced restriction of cell cycle in the G0/G1
phase by degrading cyclin D1. This result is consistent
with that published in our previous reports, and indi-
cates that cyclin D1 also plays an important role in
HUVEC proliferation. Furthermore, it has been reported
that antisense to cyclin D1 inhibited tumor-associated
neovascularization [40]. As such, suppression of cyclin
D1 expression may be one of the anti-angiogenesis
mechanisms induced by DIF-1.
Conclusions
In summary, we found that DIF-1 reduced the expres-
sion of cyclin D1 and VEGFR-2 in HUVECs. The reduc-
tion of cyclin D1 and VEGFR-2 expression may inhibit
proliferation, and reduction of VEGFR-2 may cause
inhibition of migration and tube formation. These
effects may explain the powerful anti-angiogenic proper-
ties of DIF-1.
We previously reported that DIF-1 showed anti-tumor
activity by inhibiting cyclin D1 expression and the Wnt/
b-catenin signaling pathway. In addition to these effects,
this study demonstrated that DIF-1 also exhibited anti-
angiogenic effects independent of the Wnt/b-catenin
signaling pathway. Elucidation of the target molecule of
DIF-1 will facilitate the development of potent novel
anti-tumor agents which suppresses not only the Wnt/
b-catenin signaling pathway but also angiogenesis.
Methods
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were
purchased from DS Pharma Biomedical (Osaka, Japan).
Figure 8 DIF-1 reduced VEGFR-2 mRNA level and promoter activity. (A) The effects of DIF-1 on the VEGFR-2 mRNA levels. Total RNAs were
extracted from HUVECs treated with or without DIF-1 (30 μM) for 24 h. The VEGFR-2 mRNA levels were determined by TaqMan quantitative real-
time RT-PCR. Values are mean ± SE of four independent experiments. The asterisk indicates *P < 0.05 versus control. (B and C) The effects of DIF-
1 on the human VEGFR-2 gene promoter activity on HUVECs (B) or BAECs (C). HUVECs or BAECs were co-transfected with VEGFR-2 pGL-3 and
pRL-SV40. After 24 h incubation, HUVECs and BAECs were stimulated with or without DIF-1 (30 μM) for the given periods. Luciferase activity is
shown as percentages of the control level at time 0. Values are mean ± SE of three independent experiments. The asterisk indicates *P < 0.01
**P < 0.001 ***P < 0.0001 versus control.
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ium (Sigma-Aldrich, St Louis, Mo, USA) supplemented
with 20% fetal bovine serum, 5 ng/ml (0.29 nM) recombi-
nant human basic fibroblast growth factor (PeproTech,
Rocky Hill, NJ, USA), 100 units/ml penicillin G, and
100 μg/ml streptomycin using 0.1% gelatin coated dishes.
HeLa cells (human cervical carcinoma cell line) and
bovine aortic endothelial cells (BAECs) were grown in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-
Aldrich) supplemented with 10% fetal bovine serum,
100 units/ml penicillin G and 100 μg/ml streptomycin.
Reagents and antibodies
DIF-1 (1-(3,5-dichloro-2, 6-dihydroxy-4-methoxyphenyl)-
1-hexanone) was synthesized as described previously
[41]. MG132 was obtained from the Peptide Institute
(Osaka, Japan). Cycloheximide was obtained from Sigma-
Aldrich. Polyclonal anti-cyclin D1 antibody, polyclonal
anti-PECAM-1 (CD31) antibody and the polyclonal anti-
VEGFR-1/Flt-1 antibody were purchased from Santa
Cruz Biotechnology (CA, USA). Monoclonal anti-
VEGFR-2 antibody and the monoclonal anti-phospho-
VEGFR-2 (Tyr
1175)a n t i b o d yw e r ef r o mC e l lS i g n a l i n g
Technology (Danvers, MA, USA). The monoclonal
GAPDH antibody was obtained from Abcam (Cam-
b r i d g e ,M A ,U S A ) .G r o w t hf actor reduced Matrigel was
obtained from BD Biosciences (San Jose, CA, USA).
TOPflash (TCF reporter plasmid) and FOPflash (negative
control of TOPflash) were purchased from Upstate
Biotechnology (Lake Placid, NY, USA). Human Wnt3a
was from R&D Systems (Minneapolis, MN, USA).
Cell proliferation assay
The cells were plated on 24-well plates (1.0×10
4 cells/
well) and treated with or without various amounts of
DIF-1 for defined periods. Cells were harvested by tryp-
sin/EDTA treatment and enumerated using Coulter
Counter (Beckman Coulter, Brea, CA, USA).
Flow Cytometry
Cells harvested by trypsin/EDTA treatment were sus-
pended in hypotonic fluorochrome solution containing
50 μg/ml of propidium iodide, 0.1% sodium citrate, and
0.1% Triton X-100. Cells (5×10
3) for each sample were
Figure 9 DIF-1 suppressed Wnt/b-catenin signaling pathway in HUVECs. (A) Effect of DIF-1 on TCF transcriptional activity. TOPflash or
FOPflash was co-transfected with pRL-SV40 into HUVECs. After 24 h incubation, HUVECs were stimulated with or without DIF-1 (30 μM) for 24 h.
Luciferase activity is shown as percentages of the control level. Values are mean ± SE of three independent experiments. The asterisk indicates
*P < 0.01 versus control. (B) DIF-1 activated GSK-3b. HUVECs were incubated with or without DIF-1 (30 μM) for given periods. Protein samples
were subjected to Western blot analysis for phosphorylation level of Ser
9 on GSK-3b. The membrane was reprobed with the anti-GSK-3b
antibody. The levels of protein bands were quantified and are shown as percentage of the control level at time 0. Values are mean ± SE of three
independent experiments. The asterisk indicates *P < 0.0001 versus control.
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Page 11 of 15analyzed for fluorescence by a Becton-Dickinson FACS-
calibur (Franklin Lakes, NJ, USA).
Western blotting
Samples were separated by 10 or 12% SDS-PAGE and
transferred to a polyvinylidene difluoride membrane
using a semidry transfer system (1 h, 12 V). After block-
ing with 5% skim milk, the membrane was probed with
a first antibody. Incubation was carried out overnight at
4°C. The membrane was then washed three times and
incubated with horseradish peroxidase-conjugated anti-
rabbit IgG or anti-mouse IgG (Bio-Rad, Hercules, CA,
USA) for 1 h. Immunoreactive proteins on the mem-
brane were visualized by treatment with a detection
reagent (LumiGLO, Cell Signaling Technology). Optical
densitometric scan was performed using NIH Image J
software.
Tube formation assay
Tube formation assay was performed as previously
described [42] with slight modification. Briefly, Matri-
gel was thawed at 4°C and 250 μlo ft h es o l u t i o nw e r e
added to each well in a 24-well plate and formed a gel
at 37°C for 30 min. HUVECs were suspended at 3×10
4
cells in 500 μl of 3% FBS with or without 30 μMD I F -
1, and then added to each well. After 8 h-incubation,
the degree of tube formation was determined by
counting the number of areas surrounded by tubes
contained in 10 random fields, and expressed as mean
±S E .
Cell migration assay
The effect of DIF-1 treatment on in vitro migration of
HUVECs was determined using a Boyden Chamber
[43]. The PET membrane (8 μm pore size, Greiner
Bio-One, Frickenhausen, Germany) was pre-coated
with 10 μg of Matrigel. HUVECs were suspended at
5×10
4 cells in 100 μl of serum free DMEM with or
without 30 μM DIF-1 and seeded into the upper part
of each chamber, whereas the lower compartments
were filled with 600 μlo fD M E Ms u p p l e m e n t e dw i t h
0.1% bovine serum albumin and 20 ng/ml (0.52 nM)
VEGF. After incubation for 10 h at 37°C, non-migrated
cells were scraped off with a cotton swab. Migrated
cells on the lower surface of the membrane were fixed
with 1% glutaraldehyde for 10 min and stained with
4% crystal violet for 30 min. HUVEC migration was
quantified by counting the number of cells in ten ran-
dom fields per membrane. Data are expressed as mean
± SE of cells/fields.
Figure 10 Effects of Wnt3a on VEGFR-2. (A) Wnt3a suppressed VEGFR-2 expression. HUVECs were incubated with or without Wnt3a (200 ng/
ml = 5.35 nM) for 24 h and the samples were subjected to Western blot analysis for VEGFR-2. The levels of protein bands were quantified and
are shown as percentage of the control level at time 0. Values are mean ± SE of three independent experiments. The asterisk indicates *P < 0.05
versus control. (B) Wnt3a suppressed the VEGFR-2 promoter activity. HUVECs were co-transfected with VEGFR-2 pGL-3 or TOPflash and pRL-SV40.
After 24 h incubation, cells were stimulated with or without Wnt3a (200 ng/ml) for 12 h. Luciferase activity is shown as percentages of the
control. Values are mean ± SE of three independent experiments. The asterisk indicates *P < 0.05 versus control.
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In vivo angiogenesis was assayed as growth of blood ves-
sels from mouse subcutaneous tissue into the exogenous
Matrigel plug induced by VEGF or tumor cells [43]. For
the analysis of VEGF-induced angiogenesis, Matrigel
was prepared with 100 ng/ml (2.62 nM) VEGF, 20
units/ml heparin in the presence or absence of 30 μM
DIF-1 at 4°C. The liquid Matrigel was injected (final
volume; 500 μl) into the flanks of C57BL/6 mice (5~7
weeks, n = 7 for each group) using a cold syringe and
allowed to polymerize into a solid gel by body tempera-
ture. Seven days later, Matrigel plugs were extracted and
samples were prepared for immunohistochemical analy-
sis. To analysis for tumor-induced angiogenesis, 1×10
6
HeLa cells were mixed with liquid Matrigel in the pre-
sence or absence of 30 μM DIF-1 (final volume; 500 μl).
The mixture was injected subcutaneously in the flanks
of 6 week-old nude mice (Kyudo, Saga, Japan). Two
weeks later, the tumors were removed and samples were
prepared for Western blot and immunohistochemical
analyses. The handling and sacrificing of all animals
were carried out in accordance with nationally
prescribed guidelines, and ethical approval for studies
was granted by the Animal Care and Use Committee of
Kyushu University.
Immunohistochemical analysis
The removed Matrigel plugs and tumors were fixed in
10% buffered formalin followed by embedding in paraf-
fin. Sections were then stained with hematoxylin-eosin
staining and immunofluorescence staining. For immuno-
fluorescence staining, primary PECAM-1/CD31 antibody
(1:50 dilution) was applied to the sections and the slides
were incubated overnight at 4°C. The secondary anti-
body (Histofine, Nichirei, Tokyo, Japan) was applied to
the sections and incubated for 1 h. The slides were sub-
sequently incubated with streptavidin-FITC (Invitrogen,
Carlsbad, CA, USA) and the fluorescence strength was
analyzed with Biozero fluorescence microscopy
(Keyence, Osaka, Japan).
Real-time quantitative reverse transcriptase-polymerase
chain reaction
Total RNAs were extracted from HUVECs using TRIzol
(Invitrogen) and SV total RNA isolation system (Promega,
Madison, WI, USA). First-strand cDNAs were synthesized
from 2 μg of total RNA using a high-capacity cDNA
reverse transcription kit (Applied Biosystems, Carlsbad,
CA, USA). The 100 ng cDNA products were used for
quantitative real-time PCR performed using TaqMan Uni-
versal PCR Master Mix (Applied Biosystems) and TaqMan
MGB primers [VEGFR-2 (Hs00911700_m1) and GAPDH
(Hs99999905_m1)] with an ABI Prism 7500 (Applied
Biosystems). The following PCR conditions were used: 50°
C for 2 minutes, then 95°C for 10 minutes, followed by 40
cycles at 95°C for 15 seconds and 60°C for 1 minute. Cycle
threshold (CT) values for each gene were obtained for
each sample. Differences in CT values between VEGFR-2
gene and endogenous control (GAPDH) were calculated
and used for statistical analyses.
Construction of reporter plasmid
The 5’-flanking region of human VEGFR-2 [44] was
amplified and cloned into PCR 2.1 (Invitrogen) for DNA
sequencing. After confirming the sequence, DNA frag-
ments (-1003/-48 bp relative to the transcription start
site) were excised with SacIa n dBglI Ia n dc l o n e di n t o
pGL3-Basic vectors (Promega).
Luciferase reporter gene assay
Cells were transiently transfected with plasmid DNA
(TOPflash, FOPflash orVEGFR-2/pGL-3) and pRL-
SV40, a Renilla luciferase expression plasmid (Pro-
mega) to control transfection efficacy, using Superfect
reagent (Qiagen, Hilden, Germany). To measure luci-
ferase activities, Dual-luciferase Reporter Assay (Pro-
mega) and a luminometer (Lumat LB 9507; Berthold
Technologies, Bad Wildbad, Germany) were used. Fire-
fly luciferase activities were normalized to that of
Renilla luciferase.
Statistics
The results are expressed as mean ± SE. Statistical ana-
lysis of the differences between values were conducted
using the Student’s t-test or the one-way ANOVA with
Bonferroni post-hoc tests (GraphPad Prism 5.0, Graph-
Pad Software, La Jolla, CA, USA). A P value < 0.05 was
considered statistically significant.
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